Keros Therapeutics Inc (KROS)
60.35
-2.72
(-4.31%)
USD |
NASDAQ |
Nov 14, 16:00
60.35
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Revenue (Quarterly): 0.388M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.388M |
| June 30, 2024 | 0.037M |
| March 31, 2024 | 0.083M |
| December 31, 2023 | 0.143M |
| September 30, 2023 | 0.008M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 20.00M |
| Date | Value |
|---|---|
| September 30, 2021 | |
| June 30, 2021 | 0.10M |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 2.50M |
| September 30, 2019 | 2.50M |
| June 30, 2019 | 2.50M |
| March 31, 2019 | 2.50M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.008M
Minimum
Sep 2023
20.00M
Maximum
Dec 2021
2.907M
Average
0.1215M
Median
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| Regeneron Pharmaceuticals Inc | 3.721B |
| Scholar Rock Holding Corp | -- |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | 0.35M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -52.96M |
| Total Expenses (Quarterly) | 59.04M |
| EPS Diluted (Quarterly) | -1.41 |
| Enterprise Value | 2.024B |
| Profit Margin (Quarterly) | -13.65K% |
| Earnings Yield | -8.63% |
| Normalized Earnings Yield | -9.611 |